Shanghai, China - As a new generation of TAVI product developed by MicroPort^® CardioFlow Medtech Corpration, VitaFlow Liberty^® is the first and only motorized retrievable transcatheter aortic valve system in the world. Recently, MicroPort^® CardioFlow team accompanied the expert team from four renowned hospitals in Thailand to Xiamen Cardiovascular Hospital Xiamen University to observe the successful implantation of a patient with moderate aortic stenosis combined with severe regurgitation by the local physician team using the product, which has been reprinted and reported by a number of media outlets.

In July, MicroPort^® CardioFlow Medtech Corpration (hereinafter referred to as " MicroPort^® CardioFlow") and Xiamen Cardiovascular Hospital Xiamen University  (hereinafter referred to as "the hospital") jointly carried out international exchange activities, and hosted academic experts from four well-known hospitals in Thailand for several days to conduct exchange and observation activities for the first time, deeply discussing the new progress in interventional diagnosis and treatment of valvular diseases, and exchanging international experience in the field of structural heart disease.

During the period, the Thai expert team observed the successful aortic valve implantation surgery completed by the local physician team for a patient with moderate aortic stenosis combined with severe regurgitation. The surgery used Vitaflow Liberty^®  Transcatheter Aortic Valve and Retrievable Delivery System (hereinafter referred to as "Vitaflow Liberty^®") self-developed by MicroPort^® CardioFlow. As a new generation of TAVI products, VitaFlow Liberty^® inherits the advantages of Vitaflow^®  Transcatheter Aortic Valve System in valve design, and adopts hybrid cell density frame, bovine pericardial valve leaflet and high double-layer PET skirt design, which has excellent performance such as high radial force, better coaxial release, and effective reduction of postoperative perivalvular leakage and regurgitation . In addition, its breakthrough upgraded delivery system has a unique double reinforced spiral capsule, which achieves the flexibility and 360°range of motion, while ensuring fast, stable and precise release and recapture. The Thai expert team highly praised the excellent performance of VitaFlow Liberty^® during the surgery, and expressed their favorite for the product and strong interest in learning.

Previously, MicroPort^® CardioFlow 's transcatheter aortic valve product Vitaflow^® and its second-generation product VitaFlow Liberty^®, heart valve balloon catheter Alwide^® and its second-generation product Alwide^® Plus had received marketing approval from Thailand Food and Drug Administration (Thailand FDA).This time, The Thai expert team came to China and went to the hospital with MicroPort^® CardioFlow’s team to observe the VitaFlow Liberty^® implantation surgery at close range, and to have in-depth exchange on the operation points, main performance and clinical manifestations of the product, which laid a solid foundation for further business cooperation in the future.

Prof. Kid Bhumimuang, a specialist in Thailand, said, "The motorized delivery system of VitaFlow Liberty^® can be easily operated independently by only one physician, which greatly simplifies the surgical process, saves surgical time, and provides a great deal of convenience for the physician."

Prof. Siriporn Athisakul, an expert in Thailand, said, "The product's motorized delivery system released very stable during surgery, with no power carried onto the valve and the valve remains stationary upon final release. In addition, the product's retrievable feature also solved the problem of 'difficult positioning', all these unique advantages improved the success rate of the surgery to a great extent."

Mrs Li, 81 years old, diagnosed with moderate aortic stenosis combined with moderate-to-severe regurgitation at the hospital two years ago, opted for conservative treatment at that time, instead of surgical treatment recommended by the physician. In the past six months, Mrs Li's symptoms had worsened significantly, with persistent shortness of breath even when sitting. At the return visit, she was diagnosed with severe aortic regurgitation and obvious enlargement of her heart, combined with severe mitral regurgitation, resulting in the end-stage heart failure, and her life would be in great danger without surgical treatment.

Considering the patient's advanced age, high difficulty and surgical risk, the physician team decided to use VitaFlow Liberty^®, which was self-developed by MicroPort^® CardioFlow, to minimally invasively replace Mrs Li 's damaged aortic valve. After the surgery, Mrs Li 's symptoms were significantly improved. The success of the surgery demonstrated to foreign experts China's leading technology in heart valve intervention and the superior performance of the self-developed device.

As China's first and the world's only motorized retrievable transcatheter aortic valve system, VitaFlow Liberty^® leads China's TAVI industry into the era of motorized retrievability. In the future, in addition to TAVI products, MicroPort^® CardioFlow will also build up the core competitiveness of multiple product lines through independent as well as joint research and development with global partners, so as to provide total solutions for structural heart diseases, providing high-quality, universal total solutions for structural heart disease.